Hemorheology in systemic ultrahigh-dose thrombolytic therapy with streptokinase and urokinase

Thromb Res. 1989 Oct 15;56(2):277-87. doi: 10.1016/0049-3848(89)90169-2.

Abstract

The course of fibrinogen (Fgen), red cell aggregation (RCA), plasma viscocity (PV), platelet aggregation (PA) and hematocrit (Hc) was studied in patients with ultrahigh - dose thrombolytic therapy (1.5 x 10(6) units/hour for 6 hours = 1 cycle) with streptokinase (SK) or urokinase (UK) over a period of 3 cycles. Both ultrahigh - dose SK and UK produced significant changes in the course of Fgen, RCA and PV, whereas PA (spontaneous and ADP-induced) and Hc remained unchanged. After termination of each cycle Fgen progressively increased while RCA and PV further decreased. The extent of alteration in cycle 1 - concerning the baseline values - was more pronounced with SK than with UK, but the overall effect of SK decreased through the consecutive cycles because of more rapid increase during the SK-free period. In UK-therapy hemorheological alterations were initially moderate but increased from cycle to cycle.

MeSH terms

  • Adult
  • Arterial Occlusive Diseases / blood
  • Arterial Occlusive Diseases / drug therapy*
  • Blood Viscosity / drug effects
  • Erythrocyte Aggregation / drug effects
  • Female
  • Fibrinogen / metabolism
  • Hematocrit
  • Humans
  • Male
  • Middle Aged
  • Platelet Aggregation / drug effects
  • Rheology
  • Streptokinase / administration & dosage*
  • Thrombolytic Therapy*
  • Thrombophlebitis / blood
  • Thrombophlebitis / drug therapy*
  • Urokinase-Type Plasminogen Activator / administration & dosage*

Substances

  • Fibrinogen
  • Streptokinase
  • Urokinase-Type Plasminogen Activator